Biomarkers, Tumor

"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.

Descriptor ID	D014408
MeSH Number(s)	D23.101.140
Concept/Terms	Biomarkers, Tumor Biomarkers, Tumor Tumor Biomarkers Markers, Biological Tumor Tumor Markers, Biological Markers, Tumor Metabolite Tumor Metabolite Markers Metabolite Markers, Tumor Marker, Tumor Metabolite Metabolite Marker, Tumor Tumor Metabolite Marker Tumor Markers, Biologic Biologic Tumor Markers Markers, Biologic Tumor Marker, Biologic Tumor Biologic Tumor Marker Tumor Marker, Biologic Biochemical Tumor Markers Markers, Biochemical Tumor Marker, Biochemical Tumor Biochemical Tumor Marker Tumor Marker, Biochemical Tumor Markers, Biochemical Carcinogen Markers Markers, Carcinogen Markers, Neoplasm Metabolite Neoplasm Metabolite Markers Marker, Neoplasm Metabolite Metabolite Marker, Neoplasm Neoplasm Metabolite Marker Metabolite Markers, Neoplasm Biological Tumor Markers Biological Tumor Marker Tumor Marker, Biological Marker, Biological Tumor Markers, Tumor Markers, Tumor Tumor Markers Biomarkers, Cancer Cancer Biomarkers

Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".

Chemicals and Drugs [D]
Biological Factors [D23]
Biomarkers [D23.101]
Biomarkers, Tumor [D23.101.140]

Below are MeSH descriptors whose meaning is related to "Biomarkers, Tumor".

Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.

Bar chart showing 264 publications over 28 distinct years, with a maximum of 28 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1992	1	0	1
1994	1	1	2
1995	0	1	1
1997	3	1	4
1998	0	1	1
1999	0	1	1
2000	0	2	2
2001	1	2	3
2002	1	3	4
2003	5	4	9
2004	0	3	3
2005	4	3	7
2006	2	2	4
2007	4	5	9
2008	5	2	7
2009	5	7	12
2010	4	4	8
2011	9	9	18
2012	12	4	16
2013	12	11	23
2014	12	10	22
2015	10	7	17
2016	17	11	28
2017	11	10	21
2018	6	8	14
2019	3	5	8
2020	9	7	16
2021	1	2	3

Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.

Chakravarty D, Johnson A, Sklar J, Lindeman NI, Moore K, Ganesan S, Lovly CM, Perlmutter J, Gray SW, Hwang J, Lieu C, André F, Azad N, Borad M, Tafe L, Messersmith H, Robson M, Meric-Bernstam F. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. 2022 Apr 10; 40(11):1231-1258.

View in: PubMed
Luo W, Nagaria TS, Sun H, Ma J, Lombardo JL, Bassett R, Cao AC, Tan D. Expression and Potential Prognostic Value of SOX9, MCL-1 and SPOCK1 in Gastric Adenocarcinoma. Pathol Oncol Res. 2022; 28:1610293.

View in: PubMed
Gupta S, Parmar M, Cox C, Orabi C, Khalil H, Daouk S, Brown BR. Interlobular Septal Thickening in a Young Man With Dyspnea. Chest. 2021 12; 160(6):e645-e650.

View in: PubMed
Drumond-Bock AL, Bieniasz M. The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis. Mol Cancer. 2021 11 10; 20(1):145.

View in: PubMed
Luo W, Stevens TM, Stafford P, Miettinen M, Gatalica Z, Vranic S. NUTM1-Rearranged Neoplasms-A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations-An Updated Review. Curr Oncol. 2021 11 07; 28(6):4485-4503.

View in: PubMed
Rai R, Kennedy AL, Isingizwe ZR, Javadian P, Benbrook DM. Similarities and Differences of Hsp70, hsc70, Grp78 and Mortalin as Cancer Biomarkers and Drug Targets. Cells. 2021 11 03; 10(11).

View in: PubMed
Singh D, Dheer D, Samykutty A, Shankar R. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development. J Control Release. 2021 12 10; 340:1-34.

View in: PubMed
McBride JD, McAfee JL, Piliang M, Bergfeld WF, Fernandez AP, Ronen S, Billings SD, Ko JS. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms. J Cutan Pathol. 2022 Mar; 49(3):220-230.

View in: PubMed
Farcas M, Gatalica Z, Trpkov K, Swensen J, Zhou M, Alaghehbandan R, Williamson SR, Magi-Galluzzi C, Gill AJ, Tretiakova M, Lopez JI, Montiel DP, Sperga M, Comperat E, Brimo F, Yilmaz A, Siadat F, Sangoi A, Gao Y, Ptákova N, Kuthi L, Pivovarcikova K, Rogala J, Agaimy A, Hartmann A, Fraune C, Rychly B, Hurnik P, Durcansky D, Bonert M, Gakis G, Michal M, Hora M, Hes O. Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases. Mod Pathol. 2022 03; 35(3):344-351.

View in: PubMed
Zaki MM, Mashouf LA, Woodward E, Langat P, Gupta S, Dunn IF, Wen PY, Nahed BV, Bi WL. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations. Sci Rep. 2021 09 09; 11(1):18009.

View in: PubMed

People

Explore

Similar Concepts

Top Journals